Cliona M. Rooney

46.9k total citations · 13 hit papers
388 papers, 31.4k citations indexed

About

Cliona M. Rooney is a scholar working on Oncology, Immunology and Epidemiology. According to data from OpenAlex, Cliona M. Rooney has authored 388 papers receiving a total of 31.4k indexed citations (citations by other indexed papers that have themselves been cited), including 312 papers in Oncology, 196 papers in Immunology and 137 papers in Epidemiology. Recurrent topics in Cliona M. Rooney's work include CAR-T cell therapy research (187 papers), Immune Cell Function and Interaction (135 papers) and Cytomegalovirus and herpesvirus research (131 papers). Cliona M. Rooney is often cited by papers focused on CAR-T cell therapy research (187 papers), Immune Cell Function and Interaction (135 papers) and Cytomegalovirus and herpesvirus research (131 papers). Cliona M. Rooney collaborates with scholars based in United States, Germany and France. Cliona M. Rooney's co-authors include Helen E. Heslop, Malcolm K. Brenner, Gianpietro Dotti, Barbara Savoldo, Adrian P. Gee, Catherine M. Bollard, Robert A. Krance, Ann M. Leen, Stephen Gottschalk and Hao Liu and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Cliona M. Rooney

382 papers receiving 30.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

2011 1.2k citations Gianpietro Dotti, Karin Straathof et al. profile →
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

1995 942 citations Cliona M. Rooney, Catherine Y. Ng et al. profile →
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

2008 919 citations Barbara Savoldo, Claudia Rössig et al. profile →
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma

2011 882 citations Chrystal U. Louis, Barbara Savoldo et al. Blood profile →
Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients

1998 859 citations Cliona M. Rooney, Catherine Y. Ng et al. Blood profile →
CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

2011 794 citations Barbara Savoldo, Carlos A. Ramos et al. profile →
Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes

1996 668 citations Helen E. Heslop, Catherine Y. Ng et al. profile →
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

2009 589 citations Helen E. Heslop, Catherine M. Bollard et al. Blood profile →
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15

2014 569 citations Carlos A. Ramos, Hao Liu et al. Blood profile →
An inducible caspase 9 safety switch for T-cell therapy

2005 560 citations Karin Straathof, Gianpietro Dotti et al. Blood profile →
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

2017 391 citations Chrystal U. Louis, Barbara Savoldo et al. Molecular Therapy profile →
Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins

2013 384 citations Catherine M. Bollard, Stephen Gottschalk et al. profile →
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

2025 14 citations Sandhya Sharma, Mae Woods et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cliona M. Rooney United States	93	24.6k	12.6k	8.8k	6.7k	6.3k	388	31.4k
Helen E. Heslop United States	84	21.3k 0.9×	10.8k 0.9×	7.7k 0.9×	5.4k 0.8×	5.6k 0.9×	426	28.1k
Malcolm K. Brenner United States	98	24.0k 1.0×	13.0k 1.0×	10.1k 1.1×	5.4k 0.8×	9.2k 1.4×	492	35.7k
Stanley R. Riddell United States	98	20.5k 0.8×	16.1k 1.3×	7.1k 0.8×	6.5k 1.0×	7.8k 1.2×	303	34.0k
Bruce L. Levine United States	76	22.8k 0.9×	13.9k 1.1×	7.8k 0.9×	1.3k 0.2×	9.2k 1.5×	255	32.7k
Adrian P. Gee United States	56	9.6k 0.4×	5.3k 0.4×	3.4k 0.4×	2.1k 0.3×	3.2k 0.5×	222	14.5k
Gianpietro Dotti United States	84	19.3k 0.8×	10.4k 0.8×	6.4k 0.7×	837 0.1×	7.7k 1.2×	287	26.5k
Philip D. Greenberg United States	74	11.4k 0.5×	15.2k 1.2×	3.6k 0.4×	4.3k 0.6×	4.5k 0.7×	246	22.5k
Barbara Savoldo United States	66	14.0k 0.6×	6.5k 0.5×	4.8k 0.5×	983 0.1×	4.4k 0.7×	207	16.6k
Catherine M. Bollard United States	57	8.1k 0.3×	5.5k 0.4×	2.9k 0.3×	3.0k 0.4×	1.7k 0.3×	367	12.6k
Simon F. Lacey United States	50	11.9k 0.5×	4.5k 0.4×	3.6k 0.4×	1.1k 0.2×	3.9k 0.6×	157	15.0k

Countries citing papers authored by Cliona M. Rooney

Since Specialization

Citations

This map shows the geographic impact of Cliona M. Rooney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cliona M. Rooney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cliona M. Rooney more than expected).

Fields of papers citing papers by Cliona M. Rooney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cliona M. Rooney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cliona M. Rooney. The network helps show where Cliona M. Rooney may publish in the future.

Co-authorship network of co-authors of Cliona M. Rooney

This figure shows the co-authorship network connecting the top 25 collaborators of Cliona M. Rooney. A scholar is included among the top collaborators of Cliona M. Rooney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cliona M. Rooney. Cliona M. Rooney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Zhiwei, Helen E. Heslop, Rayne H. Rouce, et al.. (2025). Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas. Blood Advances. 9(7). 1658–1669.

Shafer, Paul, Mae Woods, Jong Min Choi, et al.. (2024). Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing. Cytotherapy. 26(3). 266–275. 1 indexed citations

Ng, Chee H., Cheah C. Seh, Richard Ong, et al.. (2024). Novel OX40 and 4-1BB derived spacers enhance CD30 CAR activity and safety in CD30 positive lymphoma models. Molecular Therapy. 32(10). 3504–3521. 3 indexed citations

Ramos, Carlos A., David H. Quach, Premal Lulla, et al.. (2023). OFF‐THE‐SHELF CD30.CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC T CELLS (CD30.CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL). Hematological Oncology. 41(S2). 83–85. 8 indexed citations

Omer, Bilal, Thomas Pfeiffer, Sandhya Sharma, et al.. (2022). A Costimulatory CAR Improves TCR-based Cancer Immunotherapy. Cancer Immunology Research. 10(4). 512–524. 19 indexed citations

Sauer, Tim, Kathan Parikh, Sandhya Sharma, et al.. (2021). CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 138(4). 318–330. 142 indexed citations

Parihar, Robin, Charlotte Helena Rivas, Bilal Omer, et al.. (2019). NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunology Research. 7(3). 363–375. 219 indexed citations

Shum, Thomas, Bilal Omer, Haruko Tashiro, et al.. (2017). Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discovery. 7(11). 1238–1247. 220 indexed citations

Tanaka, Miyuki, Haruko Tashiro, Bilal Omer, et al.. (2017). Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. Clinical Cancer Research. 23(14). 3499–3509. 81 indexed citations

10.

Mata, Melinda, Juan F. Vera, Claudia Gerken, et al.. (2014). Toward Immunotherapy With Redirected T Cells in a Large Animal Model. Journal of Immunotherapy. 37(8). 407–415. 52 indexed citations

11.

Wood, Deborah, Robin L. Wesselschmidt, Peiman Hematti, et al.. (2014). An Update from the United States National Heart, Lung, and Blood Institute‐funded Production Assistance for Cellular Therapies (PACT) Program: A Decade of Cell Therapy. Clinical and Translational Science. 7(2). 93–99. 5 indexed citations

12.

Leen, Ann M., Catherine M. Bollard, Adam Mendizabal, et al.. (2013). Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 121(26). 5113–5123. 392 indexed citations

13.

Perna, Serena, Biagio De Angelis, Daria Pagliara, et al.. (2012). Interleukin 15 Provides Relief to CTLs from Regulatory T Cell–Mediated Inhibition: Implications for Adoptive T Cell–Based Therapies for Lymphoma. Clinical Cancer Research. 19(1). 106–117. 63 indexed citations

14.

Nakazawa, Yozo, et al.. (2012). <em>piggyBac</em> Transposon System Modification of Primary Human T Cells. Journal of Visualized Experiments. e4235–e4235. 14 indexed citations

15.

Cruz, Carolina Colli, Ulrike Gerdemann, Ann M. Leen, et al.. (2011). Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4. Clinical Cancer Research. 17(22). 7058–7066. 56 indexed citations

16.

Shaffer, Donald R., Andrea M. Sheehan, Zhongzhen Yi, et al.. (2011). Aggressive peripheral CD70‐positive t‐cell lymphoma associated with severe chronic active EBV infection. Pediatric Blood & Cancer. 59(4). 758–761. 5 indexed citations

17.

Kamdar, Kala Y., Cliona M. Rooney, & Helen E. Heslop. (2011). Posttransplant lymphoproliferative disease following liver transplantation. Current Opinion in Organ Transplantation. 16(3). 274–280. 58 indexed citations

18.

Louis, Chrystal U., Karin Straathof, Catherine M. Bollard, et al.. (2010). Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma. Journal of Immunotherapy. 33(9). 983–990. 160 indexed citations

19.

Savoldo, Barbara, Cliona M. Rooney, Rubén E. Quirós‐Tejeira, et al.. (2005). Cellular Immunity to Epstein-Barr Virus in Liver Transplant Recipients Treated with Rituximab for Post-Transplant Lymphoproliferative Disease. American Journal of Transplantation. 5(3). 566–572. 62 indexed citations

20.

Ng, Catherine Y., Helen E. Heslop, Martha Holladay, et al.. (1995). Production of Genetically Modified Epstein-Barr Virus-Specific Cytotoxic T Cells for Adoptive Transfer to Patients at High Risk of EBV-Associated Lymphoproliferative Disease. Journal of Hematotherapy. 4(2). 73–79. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact